Model: 184-B5/HER End Point Biomarker Treatmenta Concentration 2-OHE1: 16α-OHE1b AI Coloniesc DMSO 0.1% 0.5 ± 0.2d 20.5 ± 1.4f I3C 50 µM 9.7 ± 2.1e 9.2 ± 3.3g

Table 3: Modulation of End Point Biomarkers in Model for HER-2 Enriched Molecular Sub type of Breast cancer. aI3C at its maximum cytostatic concentration. bConcentration of individual E2 metabolites determined by the tritium exchange assay after a 48 hr treatment. Mean ± SD, N=3 per treatment group. Data analyzed by the 2-sample t-test comparing with the data from the DMSO group (Control). cAnchorage independent (AI) colony counts at day 21 post seeding of 1,000 cell per well of Six well plates. Mean±SD, N=18 per treatment group. Data analyzed by the 2-sample t test comparing the data from the DMSO group (Control). d-eP=0.004, f-gP=0.01